Theoretically, IL-1β neutralization could also benefit patients with chronic autoinflammatory diseases such as rheumatoid arthritis [48], as well as type 2 diabetes, which is also considered as a chronic low-grade inflammatory disease [49]. Here, IL1B is linked to type 2 diabetes mellitus.